Over 500 patients in and availability of high quality biological materials SPECTAcolor’s successful start has demonstrated its viability to facilitate next generation cancer clinical trials. womens air jordan Nike Air Max 2017 Heren blauw Nike Air Max 2016 Heren It has been successfully implemented across 21 clinical centers located in nine countries in Europe, cheap… Read more »
SAN DIEGO and BRUSSELS–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, and the European Organisation for Research and Treatment of Cancer (EORTC) today announced that they will collaborate via EORTC’s Screening Patients for Efficient Clinical Trial Access (SPECTA) biomarker screening initiative to identify patients who harbor a gene rearrangement to NTRK1, NTRK3, ROS1… Read more »
Cambridge, UK: 16 November 2015. Chaussures Asics Homme tn requin pas cher 14M Genomics (“14MG”) and The European Organisation for Research and Treatment of Cancer (“EORTC”) today announce the delivery of initial genomic mutation analyses conducted on newly diagnosed cancer patients as part of the EORTC Screening Patients for Efficient Clinical Trial Access (SPECTA) programme…. Read more »
This quarterly edition is dedicated to clinical trials and what they are all about. But first let us provide you with a brief update on the project patients’ status of enrollment. Today, the EORTC is proud to announce that 208 patients have been enrolled in the biobank to be entered in biomarker-led clinical trials. Good… Read more »
NEW! First patients with colorectal cancer enrolled in the EORTC SPECTAcolor Biobanking Project A new approach in treating patients with advanced colorectal cancer: Biomarker based personalized medicine advances to benefit cancer patients! A Biobank purely dedicated to colorectal cancer: Where colorectal cancer facts and figures speak for themselves… Colorectal cancer (CRC) – Cancer of the… Read more »
The EORTC is pleased to announce that SPECTAcolor, Screening Platform for Efficient Clinical Trial Access, has opened, and the first patients have enrolled. SPECTAcolor, the first Pan European collaborative molecular screening platform in colorectal cancer, will test molecular alterations in patients who are then screened for downstream biomarker-led clinical trials.
On 29 September 2012, fjallraven kanken sale adidas Stan Smith scarpe Professor Sabine Tejpar, Ray Ban Goedkoop soldes adidas pas cher co-Principal Investigator of SPECTAcolor,
To launch the roll-out the project, Nike air max 90 pas cher nike air max 90 femme EORTC and Alliance Boots held a joint press conference on March 14th 2012 in Brussels, Ray Ban Nike Air Max Baratas in the presence of HRH Princess Astrid, Fjällräven Kånken Barn nike air max 90 homme pas cher… Read more »
Alliance Boots and EORTC join forces to support pan-European cancer research with a newly established partnership in aid of the SPECTAcolor biobank.